Parkland Memorial Hospital
Parkland Memorial Hospital
Dallas, Texas, United States121 results ยท Page 1 of 5
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer | Locally Advanced Cervical Adenocarcinoma; Locally Advanced Cervical Adenosquamous Carcinoma; Locally Advanced Cervical Squamous Cell Carcinoma; Stage IIIA Cervical Cancer FIGO 2018; Stage IIIB Cervical Cancer FIGO 2018; Stage IIIC1 Cervical Cancer FIGO 2018; Stage IIIC2 Cervical Cancer FIGO 2018; Stage IVA Cervical Cancer FIGO 2018 | Recruiting | Phase 3 | 2026-10-09 | NCT07061977 | |
| Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | Adnexal Diseases, Carcinoma, Endometrioid, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, carcinoma, endocrine system disorder, endometrial clear cell adenocarcinoma, endometrial endometrioid adenocarcinoma, endometrial mucinous adenocarcinoma, endometrial undifferentiated carcinoma, endometrium adenocarcinoma, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, neoplasm, ovarian cancer, ovarian disorder, uterine disorder | Recruiting | Phase 2 | 2026-10-09 | NCT05112601 | |
| Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-10-09 | NCT04181060 | |
| Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial | Neoplasms by Site, Thoracic Neoplasms, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-10-08 | NCT06096844 | |
| Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung | Advanced Extrapulmonary Neuroendocrine Carcinoma; Metastatic Extrapulmonary Neuroendocrine Carcinoma; Recurrent Extrapulmonary Neuroendocrine Carcinoma; Unresectable Extrapulmonary Neuroendocrine Carcinoma | Recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT05058651 | |
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | pancreatic acinar cell carcinoma, pancreatic adenosquamous carcinoma, squamous cell carcinoma of pancreas | Recruiting | Phase 2 | 2026-10-08 | NCT04858334 | |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | renal pelvis/ureter urothelial carcinoma | Recruiting | Phase 2 / Phase 3 | 2026-10-08 | NCT04628767 | |
| Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 3 | 2026-10-08 | NCT04267848 | |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 3 | 2026-10-08 | NCT03678025 | |
| Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) | female reproductive organ cancer | Recruiting | Phase 2 | 2026-10-07 | NCT06126276 | |
| NCI COVID-19 in Cancer Patients, NCCAPS Study | COVID-19, Coronaviridae Infections, Infections, Neoplasm Metastasis, Neoplastic Processes, Nidovirales infectious disease, Orthocoronavirinae infectious disease, Pathologic Processes, Pathological Conditions, Signs and Symptoms, RNA Virus Infections, lung disorder, neoplasm, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Active, not recruiting | Not stated | 2026-10-07 | NCT04387656 | |
| Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity | Abdominal Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Peritoneal Diseases, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, neoplasm, peritoneal neoplasm | Recruiting | Phase 2 / Phase 3 | 2026-10-05 | NCT07001748 | |
| A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer | Neoplasms by Histologic Type, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma | Recruiting | Phase 3 | 2026-10-05 | NCT06524544 | |
| Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, castration-resistant prostate carcinoma, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Recruiting | Phase 2 | 2026-10-02 | NCT06632977 | |
| mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | esophageal adenocarcinoma | Recruiting | Phase 3 | 2026-10-02 | NCT05677490 | |
| Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, carcinosarcoma of the corpus uteri, endometrial carcinoma, endometrial clear cell adenocarcinoma, endometrial endometrioid adenocarcinoma, endometrial serous adenocarcinoma, endometrial undifferentiated carcinoma, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Active, not recruiting | Phase 3 | 2026-10-02 | NCT05256225 | |
| Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, adenocarcinoma, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, pancreas disorder, pancreatic endocrine carcinoma, pancreatic neoplasm, primitive neuroectodermal tumor, somatostatinoma | Active, not recruiting | Phase 2 | 2026-10-02 | NCT02595424 | |
| Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Nerve Tissue, central nervous system cancer, intracranial meningioma, meningioma, neoplasm, nervous system disorder, tumor of meninges, vascular cancer | Recruiting | Phase 2 | 2026-10-02 | NCT02523014 | |
| Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, invasive breast carcinoma, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2026-10-02 | NCT02445391 | |
| Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Recruiting | Phase 2 | 2026-10-01 | NCT07061964 | |
| Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers | FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma; FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma; Metastatic Endometrial Endometrioid Adenocarcinoma; Recurrent Endometrial Endometrioid Adenocarcinoma | Active, not recruiting | Phase 1 / Phase 2 | 2026-10-01 | NCT05538897 | |
| Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents | fallopian tube mucinous adenocarcinoma, ovarian seromucinous carcinoma | Active, not recruiting | Phase 2 | 2026-10-01 | NCT04739800 | |
| Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-10-01 | NCT03793179 | |
| Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Lymphatic Metastasis, Male Urogenital Diseases, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, clear cell renal carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, metastatic malignant neoplasm in the lymph nodes, neoplasm, renal cell carcinoma, rhabdoid tumor of the kidney, sarcomatoid renal cell carcinoma, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-01 | NCT03793166 | |
| Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone | Adnexal Diseases, Carcinoma, Endometrioid, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, carcinoma, carcinosarcoma, endocrine system disorder, endometrial serous adenocarcinoma, endometrial undifferentiated carcinoma, endometrium adenocarcinoma, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, mixed neoplasm, neoplasm, ovarian cancer, ovarian disorder, sarcoma | Active, not recruiting | Phase 2 | 2026-10-01 | NCT03660826 |